NRG-GY012
|
NRG
|
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
NRG-GY014
|
NRG
|
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
NRG-GY016
|
NRG
|
A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
NRG-GY017
|
NRG
|
Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently with Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
NRG-GY018
|
NRG
|
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
NRG-GY019
|
NRG
|
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
NRG-GY020
|
NRG
|
A Phase III Randomized Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
NRG-GY021
|
NRG
|
A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab In Platinum-Sensitive Recurrent Ovarian Cancer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
NRG-GY022
|
NRG
|
Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
NRG-GY023
|
NRG
|
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer who have Received Prior Bevacizumab
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|